The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Types of histiocytosis and their treatment strategies
Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, shares some insights into Langerhans cell histiocytosis (LCH) and explains how different subtypes of histiocytosis differ from one another by various factors including the driver oncogene, the clinical presentation, and by the capacity to diverge and to generate a polyclonal phenotype. The different treatment strategies for LCH and malignant histiocytosis are described. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
